« Back
Home /
Ipilimumab (anti-CTLA-4)

Ipilimumab (anti-CTLA-4)

Manufacturer	Selleckchem
Category	Oncology Antibodies By Cell Type Carcinoma Primary Antibodies
Type	Antibody
Specific against	other
Amount	1 mg x 5
Item no.	A2001-5
Targets	CD152
CASRN	477202-00-9
eClass 6.1	32160702
eClass 9.0	32160702
Available
Information	Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg x 5

available

Delivery expected until 5/16/2024